A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 166 participants.

Also called NCT06151964

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06151964
  • EU CT 2023-504215-32-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Canada, Germany, Japan, Sweden (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06151964. Randomized; triple masking; primary purpose treatment. Start 2023-09-29 (actual); primary completion 2027-01-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
Acronym
CONTEMPO
Condition
Overweight and Obesity
Intervention (Drug)
AZD9550
Intervention (Drug)
placebo
Intervention (Drug)
AZD9550 and AZD6234
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06151964
Content hash
1e9a97cc40fdeb0f562dd883a5957c8aa8e41f45dcebcb0afbe1c03d761200ba